HopeStage
Back to all studies
RecruitingNCT05973851

Esketamine-based intensified treatment or usual care after an initial treatment failure in depression

About this titleRead the official source — NCT05973851
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who could participate?

This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Innsbruck and 11 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 31, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
418
Sponsor
Dr. Inge Winter
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United Kingdom, Austria, Germany, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05973851
Official title
Show the full official title

A Randomised, Controlled Trial to Investigate the Effect of a Sixweek Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruitment & locations

Currently recruiting

Innsbruck, Austria · Bielefeld, Germany · Dortmund, Germany

9 more locations
  • Frankfurt am Main, Germany
  • Münster, Germany
  • Athens, Greece
  • Brescia, Italy
  • Cagliari, Italy
  • Naples, Italy
  • Turin, Italy
  • Barcelona, Spain
  • London, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Dr. Inge Winter.

Does this study involve medication?

Yes. The study involves medication, including Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride and Second-line Antidepressants.

Who can participate?

This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies